[1]Velavan TP, Meyer CG. The COVID19 epidemic[J].Trop Med Int Health,2020, 25(3):278-280.
[2]武汉同济医院新型冠状病毒肺炎救治协作组.重症新型冠状病毒感染肺炎诊疗与管理共识\[J\].内科急危重症杂志,2020,26(1):1-5.
[3]中华人民共和国国家卫生健康委员会.新型冠状病毒感染的肺炎诊疗方案(试行第七版)(国卫办医函\[2020\]184号)\[EB/OL\].(2020-03-03).http:∥www.gov.cn/ zhengce/zhengceku/202003/04/content_5486705.htm
[4]王汉萍,周佳鑫,郭潇潇,等.免疫检查点抑制剂相关毒副作用管理之激素的使用\[J\].中国肺癌杂志,2019,22(10):615-620.
[5]尹彦斌.糖皮质激素治疗重症肺炎研究进展\[J\].天津药学,2014,26(6):45-48.
[6]龙玲,张之阳,赵浩天,等.糖皮质激素在重症肺炎中的辅助治疗作用\[J\].国际呼吸杂志,2016,36(14):1090-1093.
[7]幸海燕,陈剑鸿.糖皮质激素治疗新型冠状病毒肺炎的有效性和安全性分析\[J\].中国药业,2020,29(5):40-43.
[8]卢林维.探讨糖皮质激素的药理作用,总结其临床应用过程中不良反应发生情况\[J\].北方药学,2019,16(9):129-130.
[9]李鑫,杨蕊.糖皮质激素的药理作用机制研究进展\[J\].国际药学研究杂志,2009, 36(1):27-30.
[10]糖皮质激素类药物临床应用指导原则.中华内分泌代谢杂志\[J\].2012,28(2): I0002-I0033.
[11]Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China\[J\].Lancet,2020,395(10223) : 497-506.
[12]武明芬,陈瑞玲,赵志刚.激素类药物在病毒性肺炎治疗中的应用与循证评价\[J\].临床药物治疗杂志,2020,18(2):80-86.
[13]杨青.小剂量糖皮质激素治疗重症社区获得性肺炎的临床分析\[J\].中国实用医药,2018,13(35):16-18.
[14]Sehgal VN,Malhotra R. Pharmacology and therapeutics of corticosteroids sparing maintenance immunosuppressive/adjunct therapy drugs\[J\].Skinmed, 2019,17(3):172-179.
[15]Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China \[J\]. Lancet, 2020,395(10223):497-506.
[16]Liu H, Li J, Chen M, et al. Glucocorticoid treatment of suspected organizing pneumonia after H7N9 infection: A case report \[J\]. Medicine (Baltimore), 2019,98(34): e16839.
[17]Wu, WF, Fang Q, He GJ. Efficacy of corticosteroid treatment for severe communityacquired pneumonia: A metaanalysis\[J\]. Am J Emerg Med, 2018,36(2):179-184.
[18]Lianhan S, Jianping Z, Yi H, et al. On the use of corticosteroids for 2019nCoV pneumonia\[J\].Lancet,2020,395(10223):683-684.
[19]Auyeung TW, Lee JS, Lai WK, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study\[J\]. J Infect, 2005, 51(2): 98-102.
[20]Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARSassociated coronavirus RNA concentrations in adult patients\[J\]. J Clin Virol, 2004, 31(4): 304-309.
[21]Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019nCoV lung injury\[J\]. Lancet, 2020,395(10223): 473-475.
[22]赵建平, 胡轶, 杜荣辉, 等.新型冠状病毒肺炎糖皮质激素使用的建议[J].中华结核和呼吸杂志,2020,43(3):183-184.
[23]索涛,范慧,陈国忠.病毒性肺炎治疗的研究进展[J/OL].武汉大学学报(医学版),2020.doi:10.14188/j.1671-8852.2020.6018.
[24]陈倩,裴茂华,王瑶,等.糖皮质激素在新型冠状病毒肺炎中应用的利与弊\[J/OL\].武汉大学学报(医学版),2020. doi:10.14188/ j.16718852.2020.0136.
[25]Metlay JP,Waterer GW,Long AC,et al.Diagnosis and treatment of adults with communityacquired pneumonia.An official clinical practice guideline of the american thoracic society and infectious diseases society of america \[J\].Am J Respir Crit Care Med,2019,200(7):e45-e67.
[26]Wan YD, Sun TW, Liu ZQ, et al. Efficacy and safety of corticosteroids for communityacquired pneumonia:a systematic review and metaanalysis\[J\].Chest, 2016,149(1):209-219.
[27]侯平,王国涛,代立娟.糖皮质激素在病毒性肺炎早期治疗中的作用\[J\].黑龙江医药科学,2019,42(5):72-73.
[28]Wilkinson TM, Li CK, Chui CS, et a1. Preexisting in fluenzaspecific CD4+ T cells correlate with disease protection against influenza challenge in humans\[J\].Nat Med,2012,l8(2):274-280.
[29]李兴旺,蒋荣猛,郭嘉祯.糖皮质激素治疗重症急性呼吸综合征初探[J].中华内科杂志,2003,6:21-24.
[30]Yu M, Kaizhao Z, Wenbao Q, et al. Expression pattern of NLRP3 and its related cytokines in the lung and brain of avian influenza virus H9N2 infected BALB/c mice\[J\]. Virol J,2014,11(1):229.
[31]陈燕.糖皮质激素在儿科临床诊疗中的安全性及合理性分析\[J\].临床合理用药杂志,2020,13(6):65-66.
[32]刘慧,谢集健,张玮.产前肌注糖皮质激素对早产小于胎龄儿病死率和主要并发症的影响\[J\].临床和实验医学杂志,2018,17(15):1676-1679.
[33]吴华,章友康.妊娠及哺乳期女性糖皮质激素和免疫抑制剂的合理应用\[J\].中华肾病研究电子杂志,2018,7(6):241-244.
[34]顾有守.全身应用糖皮质激素的不良反应及防治对策\[J\].皮肤病与性病,2016,38(1):16-18.
[35]石文磊.糖皮质激素对血压调节允许作用的非基因组机制\[D\].上海:第二军医大学,2007.
[36]Hong D, Chen HX, Yu HQ, et a1. Quantitative proteomic analysis of dexamethasoneinduced effects on osteoblast differentiation proliferation, and apoptosis in MC3T3E1 cells using SILAC\[J\].Osteoporosis International, 2011,22:2175-2186.
[37]黄倩,李宝善,梁霄,等.克老素抑制地塞米松诱导的MC3T3E1成骨细胞凋亡[J].中国药理学通报,2018,34(4): 570-576.
[38]首健,陈佩杰,肖卫华.糖皮质激素对骨骼肌代谢的调控及其机制\[J\].中国药理学通报,2019,35(5):602-606.
[39]Ducharme FM, Dell SD, Radhakrishnan D,et al. Diagnosis and management of asthma in preschoolers: a canadian thoracic society and canadian paediatric society position paper\[J\].Can Respir,2015,22(3):135-143.
[40]张允健,赖天文,祝金平,等.长期大剂量糖皮质激素对哮喘大鼠消化道HIF1α/VEGF通路的影响\[J\].西部医学,2019,31(11):1690-1694.
[41]柏愚,李延青,任旭,等.应激性溃疡防治专家建议(2018版)\[J\].中华医学杂志,2018,98(42):3392-3395.
[42]李嫔.内分泌疾病相关的电解质紊乱及救治措施\[J\].中国小儿急救医学,2016,23(10):673-677.
[43]吴云丹,崔路坤.地塞米松致重度低钾血症1例\[J\].汕头大学医学院学报,2019,32(2):127-128.
[44]杨柳,甘建和,冯婷婷,等.糖皮质激素治疗急性肝损伤期间的血糖升高\[J\].江苏医药,2012,38(23):2801-2803.
[45]高桂凤,王旭光,刘凌,等.原发性肾小球疾病应用糖皮质激素致糖代谢异常分析及临床干预\[J\].中国实用医刊,2011,38(9):60-61.
|